This ADC product is comprised of an anti-TNFRSF8 monoclonal antibody (CA10) conjugated via a β-glucuronide linker to a Camptothecin Analog.
ADC Target
- Alternative Names
- TNFRSF8; tumor necrosis factor receptor superfamily, member 8; CD30; Ki-1; D1S166E; tumor necrosis factor receptor superfamily member 8; Ki-1 antigen; CD30L receptor; cytokine receptor CD30; lymphocyte activation antigen CD30;
- Target Entrez Gene ID
- 943
- Overview
- The protein encoded by this gene is a member of the TNF-receptor superfamily. This receptor is expressed by activated, but not by resting, T and B cells. TRAF2 and TRAF5 can interact with this receptor, and mediate the signal transduction that leads to the activation of NF-kappaB. This receptor is a positive regulator of apoptosis, and also has been shown to limit the proliferative potential of autoreactive CD8 effector T cells and protect the body against autoimmunity. Two alternatively spliced transcript variants of this gene encoding distinct isoforms have been reported.
ADC Antibody
- Overview
- Chimeric Anti-TNFRSF8 Antibody, cAC10
ADC Linker
- Name
- β-glucuronide linker
- Description
- β-Glucuronide linkers belong to Enzymatically cleavable linkers, which have expected stability and provide facile release of the active drug. The cleavage of the β-glucuronide glycosidic bond relies on lysosomal enzyme β-glucuronidase, and this enzyme is abundantly present within lysosomes and is overexpressed in some tumor types, while the enzyme activity outside cells is low.
ADC payload drug
- Description
- Calicheamicin,produced by prokaryotic microorganisms, are a group of DNA cleaving agents with similar structure that binds in the minor grove of DNA in a relatively sequence-specific manner.
For Research Use Only. NOT FOR CLINICAL USE.
Related Products